Effect of omeprazole on the steady-state pharmacokinetics of voriconazole.
about
Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype.Voriconazole pharmacokinetics in liver transplant recipients.Influence of CYP2C19*2/*17 genotype on adverse drug reactions of voriconazole in patients after allo-HSCT: a four-case reportImpact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole.Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients.Population pharmacokinetic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis.Pharmacokinetics of voriconazole administered concomitantly with fluconazole and population-based simulation for sequential use.Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults.Effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem in healthy subjectsMulticenter study of voriconazole pharmacokinetics and therapeutic drug monitoring.Safety and potential of drug interactions of caspofungin and voriconazole in multimorbid patients.Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignanciesSafety, Efficacy, and Exposure-Response of Voriconazole in Pediatric Patients With Invasive Aspergillosis, Invasive Candidiasis or Esophageal Candidiasis.Management of drug and food interactions with azole antifungal agents in transplant recipients.Pharmacogenomics of the triazole antifungal agent voriconazole.Azole interactions with multidrug therapy in pediatric oncology.Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014.Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.Pharmacokinetic considerations in treating invasive pediatric fungal infections.Therapeutic challenges posed by critical drug-drug interactions in cystic fibrosis.Voriconazole metabolism is influenced by severe inflammation: a prospective study.Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450(CYP) Inhibitors and/or with CYP Inhibitors plus CYP Inducers.Therapeutic drug monitoring of voriconazole helps to decrease the percentage of patients with off-target trough serum levels.Utilization of omeprazole to augment subtherapeutic voriconazole concentrations for treatment of Aspergillus infections.Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects.In vivo quantitative prediction of the effect of gene polymorphisms and drug interactions on drug exposure for CYP2C19 substratesInhibition of voriconazole metabolism by chloramphenicol in an adolescent with central nervous system aspergillosis.Disseminated Scedosporium prolificans infection in an 'extensive metaboliser': navigating the minefield of drug interactions and pharmacogenomics.Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy.Pharmacokinetic variability of voriconazole and N-oxide voriconazole measured as therapeutic drug monitoring.CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole.Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience.Safety and pharmacokinetics of coadministered voriconazole and anidulafungin.Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects.Pharmacogenomics of triazole antifungal agents: implications for safety, tolerability and efficacy.Autoinhibitory properties of the parent but not of the N-oxide metabolite contribute to infusion rate-dependent voriconazole pharmacokinetics.Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients
P2860
Q33608028-480D59CA-F58D-4E6C-B914-D8DD69AC82B9Q33613685-AE57F2B3-A598-412C-A39A-E332452E732CQ33665780-80B04BF8-CC86-4A2E-A1DF-05EACB702B72Q33726698-B8193BC9-1B67-4A45-844D-900E0311F387Q34045383-37CEE9D9-D919-4D15-BEC7-4BD086AAD45DQ34058346-F6D96449-180F-4BE9-A193-5BAC5970C4DFQ35364006-33CB6F88-B628-488F-88F6-19036BA608FBQ35598464-622C0E06-B1C2-475C-9A48-A9E4B7BB1DE1Q36024937-8BAAFAB1-F760-45B8-B24E-732F4B2EF728Q36172497-240F693E-E3FE-4E8A-B52D-11B2C0952386Q36271648-C49E9739-B794-4E1D-A33C-815057E7D124Q36927577-817D277F-3EF0-4DE9-958E-9DE74CD49FF0Q36969780-D340A4CB-73B4-4613-B121-DB2F4B6B1AD0Q37693296-47ABB49B-48BA-4D30-9362-0D2C38204653Q37775009-0B15F6BB-DAAD-48E0-AB7C-DC9530D20144Q37892536-FA5A636E-207A-42A4-A419-4E9F86F9CB90Q38015710-4BE7E640-143F-4DF4-8A47-8D0D1B4BA749Q38284468-3F4F0D02-E339-43E1-A376-DD01608C4CD0Q38681635-307D48A2-EC09-4FDC-9948-262801CBF004Q38816614-2222F111-20E1-45D5-94A4-804E2907A7C9Q38962747-D20EAB41-0F21-46F4-BC08-17C70231F40AQ39416464-1FC55BF7-02E8-4295-8FEA-B970A355C986Q40317932-4731B55B-88E2-4C61-AEBC-02191C1D11B7Q40842732-5E50FCCD-1D59-404B-89A3-5BB7D0BDF418Q41571903-EB724BB9-2D3B-4E98-9B6C-DB622A5C52A6Q41842301-5D3CEA1A-437A-4877-B6F5-2E66FC599727Q41986948-48EDACF7-5121-4F1E-99A8-9FE33512D972Q42173355-486B1DCB-B54C-4536-96EC-39631C080B32Q42218014-0B0A61ED-B8CD-4A96-A215-E41948009232Q42272330-AB590FD9-B93A-498B-9CD8-A748271A59D0Q42966049-D0DACB53-3D81-4990-AD5F-D79CFF3D188FQ44273424-D326695F-4231-4BC7-A5F9-6B3EDA9849CFQ44705704-776DF4ED-73EC-46BE-B0CC-119A21C73D86Q46807629-2F37E9D4-27EB-4A9F-823C-7F40A46751ADQ46891654-6C847ADF-E21F-40CB-90D3-20DF22195DA7Q47664190-1A0BF9E1-470E-4A1A-87CC-6D8393EA40B3Q48333024-A74CB665-8D28-49B4-8672-6D20CCBD1386Q57611765-11B58981-3BD4-4920-903D-9174F7CFE6C1
P2860
Effect of omeprazole on the steady-state pharmacokinetics of voriconazole.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Effect of omeprazole on the steady-state pharmacokinetics of voriconazole.
@en
Effect of omeprazole on the steady-state pharmacokinetics of voriconazole.
@nl
type
label
Effect of omeprazole on the steady-state pharmacokinetics of voriconazole.
@en
Effect of omeprazole on the steady-state pharmacokinetics of voriconazole.
@nl
prefLabel
Effect of omeprazole on the steady-state pharmacokinetics of voriconazole.
@en
Effect of omeprazole on the steady-state pharmacokinetics of voriconazole.
@nl
P2093
P2860
P1476
Effect of omeprazole on the steady-state pharmacokinetics of voriconazole.
@en
P2093
Diane Kleinermans
Don Nichols
Gary Layton
Julia Hamlin
Lynn Purkins
Nolan Wood
P2860
P356
10.1046/J.1365-2125.2003.02000.X
P407
P478
56 Suppl 1
P577
2003-12-01T00:00:00Z